HAE – Haemonetics Corporation
Float Short %
7.02
Margin Of Safety %
26
Put/Call OI Ratio
0.37
EPS Next Q Diff
0.17
EPS Last/This Y
1.5
EPS This/Next Y
0.63
Price
50.28
Target Price
76.1
Analyst Recom
1.64
Performance Q
-33.95
Relative Volume
0.45
Beta
0.43
Ticker: HAE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-06 | HAE | 49.54 | 0.74 | 0.13 | 10035 |
| 2025-10-07 | HAE | 49.26 | 0.73 | 0.03 | 10151 |
| 2025-10-08 | HAE | 50.98 | 0.70 | 0.25 | 10359 |
| 2025-10-09 | HAE | 50.12 | 0.72 | 0.01 | 10242 |
| 2025-10-10 | HAE | 48.81 | 0.72 | 24.76 | 10243 |
| 2025-10-13 | HAE | 50.22 | 0.55 | 1.00 | 9282 |
| 2025-10-14 | HAE | 49.72 | 0.55 | 4.15 | 9284 |
| 2025-10-15 | HAE | 48.58 | 0.57 | 0.01 | 9413 |
| 2025-10-16 | HAE | 49.79 | 0.44 | 0.07 | 11125 |
| 2025-10-17 | HAE | 50.25 | 0.42 | 3.76 | 11555 |
| 2025-10-20 | HAE | 50.71 | 0.41 | 0.45 | 5687 |
| 2025-10-21 | HAE | 51.18 | 0.41 | 0.32 | 5725 |
| 2025-10-22 | HAE | 51.36 | 0.41 | 0.45 | 5817 |
| 2025-10-23 | HAE | 51.33 | 0.41 | 0.04 | 5840 |
| 2025-10-24 | HAE | 51.22 | 0.38 | 1.34 | 6210 |
| 2025-10-27 | HAE | 51.19 | 0.39 | 0.00 | 6260 |
| 2025-10-28 | HAE | 50.35 | 0.38 | 0.46 | 6298 |
| 2025-10-29 | HAE | 49.44 | 0.38 | 3.14 | 6323 |
| 2025-10-30 | HAE | 49.99 | 0.38 | 0.59 | 6338 |
| 2025-10-31 | HAE | 50.01 | 0.37 | 0.10 | 6656 |
| 2025-11-03 | HAE | 50.26 | 0.37 | 0.32 | 6680 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-06 | HAE | 49.53 | -1.1 | 4.0 | 4.83 |
| 2025-10-07 | HAE | 49.22 | -1.1 | 0.7 | 4.83 |
| 2025-10-08 | HAE | 50.99 | -1.1 | 7.8 | 4.83 |
| 2025-10-09 | HAE | 50.13 | -1.1 | -1.0 | 4.83 |
| 2025-10-10 | HAE | 48.83 | -0.8 | -2.7 | 4.83 |
| 2025-10-13 | HAE | 50.22 | -0.8 | 6.6 | 4.83 |
| 2025-10-14 | HAE | 49.75 | -0.8 | 0.1 | 4.83 |
| 2025-10-15 | HAE | 48.56 | -0.8 | -2.3 | 4.83 |
| 2025-10-16 | HAE | 49.78 | -0.8 | 6.0 | 4.83 |
| 2025-10-17 | HAE | 50.23 | -0.8 | 3.4 | 4.83 |
| 2025-10-20 | HAE | 50.70 | -0.8 | 3.3 | 4.83 |
| 2025-10-21 | HAE | 51.19 | -0.8 | 3.5 | 4.83 |
| 2025-10-22 | HAE | 51.34 | -0.8 | 2.3 | 4.83 |
| 2025-10-23 | HAE | 51.35 | -0.8 | 1.8 | 4.83 |
| 2025-10-24 | HAE | 51.24 | -0.8 | 1.4 | 4.83 |
| 2025-10-27 | HAE | 51.22 | -0.8 | 1.7 | 4.83 |
| 2025-10-28 | HAE | 50.36 | -0.8 | -1.0 | 4.83 |
| 2025-10-29 | HAE | 49.42 | -0.8 | -1.4 | 4.83 |
| 2025-10-30 | HAE | 49.99 | -0.8 | 3.7 | 4.83 |
| 2025-10-31 | HAE | 50.01 | -0.8 | 1.9 | 4.83 |
| 2025-11-03 | HAE | 50.28 | -0.8 | 2.7 | 4.83 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-06 | HAE | 0.00 | 0.22 | 7.14 |
| 2025-10-07 | HAE | 0.00 | 0.22 | 7.14 |
| 2025-10-08 | HAE | 0.00 | 0.22 | 7.14 |
| 2025-10-09 | HAE | 0.00 | 0.22 | 7.14 |
| 2025-10-10 | HAE | 0.00 | 0.22 | 6.59 |
| 2025-10-13 | HAE | 0.00 | 0.56 | 6.59 |
| 2025-10-14 | HAE | 0.00 | 0.56 | 6.59 |
| 2025-10-16 | HAE | 0.00 | 0.56 | 6.59 |
| 2025-10-17 | HAE | 0.00 | 0.56 | 6.59 |
| 2025-10-20 | HAE | 0.00 | 0.60 | 6.59 |
| 2025-10-21 | HAE | 0.00 | 0.60 | 6.59 |
| 2025-10-22 | HAE | 0.00 | 0.60 | 6.59 |
| 2025-10-23 | HAE | 0.00 | 0.60 | 6.59 |
| 2025-10-24 | HAE | 0.00 | 0.60 | 6.59 |
| 2025-10-27 | HAE | 0.00 | 0.81 | 7.02 |
| 2025-10-28 | HAE | 0.00 | 0.81 | 7.02 |
| 2025-10-29 | HAE | 0.00 | 0.81 | 7.02 |
| 2025-10-30 | HAE | 0.00 | 0.81 | 7.02 |
| 2025-10-31 | HAE | 0.00 | 0.81 | 7.02 |
| 2025-11-03 | HAE | 0.00 | -0.19 | 7.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.1
Avg. EPS Est. Current Quarter
1.11
Avg. EPS Est. Next Quarter
1.27
Insider Transactions
Institutional Transactions
-0.19
Beta
0.43
Average Sales Estimate Current Quarter
312
Average Sales Estimate Next Quarter
328
Fair Value
63.6
Quality Score
81
Growth Score
85
Sentiment Score
34
Actual DrawDown %
64.6
Max Drawdown 5-Year %
-68.6
Target Price
76.1
P/E
15.34
Forward P/E
9.21
PEG
1.53
P/S
1.8
P/B
2.74
P/Free Cash Flow
12.8
EPS
3.28
Average EPS Est. Cur. Y
4.83
EPS Next Y. (Est.)
5.46
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
12.13
Relative Volume
0.45
Return on Equity vs Sector %
-7.2
Return on Equity vs Industry %
0.1
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
2.7
Haemonetics CorporationSector: Healthcare
Industry: Medical Devices
Employees: 3023
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
stock quote shares HAE – Haemonetics Corporation Stock Price stock today
news today HAE – Haemonetics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch HAE – Haemonetics Corporation yahoo finance google finance
stock history HAE – Haemonetics Corporation invest stock market
stock prices HAE premarket after hours
ticker HAE fair value insiders trading